GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia

Blood

Volumn 121, Issue 25, 2013, Pages 5068-5077

  Padron, Eric ^a   Painter, Jeffrey S ^a   Kunigal, Sateesh ^a   Mailloux, Adam W ^a   McGraw, Kathy ^a   McDaniel, Jessica M ^a   Kim, Eunhee ^b   Bebbington, Christopher ^c   Baer, Mark ^c   Yarranton, Geoffrey ^c   Lancet, Jeffrey ^a   Komrokji, Rami S ^a   Abdel Wahab, Omar ^b   List, Alan F ^a   Epling Burnette, Pearlie K ^a,d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c KaloBios Inc   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2 INHIBITOR; LENZILUMAB; LMM 102; MOMELOTINIB; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RUXOLITINIB; SD 1029; STAT5 PROTEIN; TG 101384; UNCLASSIFIED DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR;

ARTICLE; ASSOCIATION CONSTANT; BINDING KINETICS; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CELL EXPANSION; CELL SURVIVAL; CELL VIABILITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISSOCIATION CONSTANT; DRUG DOSE INCREASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOCYTE; LEUKOCYTE COUNT; MONOCYTE; MYELOID PROGENITOR CELL; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURFACE PLASMON RESONANCE; METABOLISM;

FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; STAT5 TRANSCRIPTION FACTOR; SURFACE PLASMON RESONANCE;

EID: 84882396666     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-460170     Document Type: Article

References (38)

1. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia. 2008;22(7):1335-1342.
2. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1): 45-52.
3. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14): 3932-3941.
4. Kohlmann A, Grossmann V, Klein H-U, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24): 3858-3865.
5. Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011; 473(7346):230-233.
6. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367): 64-69.
7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4): 451-458.
8. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5): 937-951.
9. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77(5): 925-929.
10. Ramshaw HS, Bardy PG, Lee MA, Lopez AF. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol. 2002;30(10):1124-1131.
11. Kotecha N, Flores NJ, Irish JM, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 2008;14(4): 335-343.
12. Lopez AF, Hercus TR, Ekert P, et al. Molecular basis of cytokine receptor activation. IUBMB Life. 2010;62(7):509-518.
13. Hansen G, Hercus TR, McClure BJ, et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell. 2008;134(3):496-507.
14. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385-395.
15. Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, Lopez AF. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood. 2009; 114(7):1289-1298.
16. Frankel AE, Powell BL, Hall PD, et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002; 8(5):1004-1013.
17. Frankel AE, Lilly M, Kreitman R, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 1998; 92(11):4279-4286.
18. Gaipa G, Bugarin C, Longoni D, et al. Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement. Leukemia. 2009;23(4):791-793.
19. Nishio N, Takahashi Y, Tanaka M, et al. Aberrant phosphorylation of STAT5 by granulocyte-macrophage colony-stimulating factor in infant cytomegalovirus infection mimicking juvenile myelomonocytic leukemia. Leuk Res. 2011;35(9): 1261-1264.
20. Avanzi GC, Brizzi MF, Giannotti J, Ciarletta A, Yang YC, Pegoraro L, Clark SC. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3. J Cell Physiol. 1990; 145(3):458-464.
21. Sugimori C, Padron E, Caceres G, et al. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012;2(3):e63.
22. Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119(19): 4480-4485.
23. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/ 2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
24. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2009: 636-642.
25. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/ JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23(8):1441-1445.
26. Duan Z, Bradner JE, Greenberg E, et al. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res. 2006;12(22):6844-6852.
27. Nice E, Dempsey P, Layton J, et al. Human granulocyte-macrophage colony-stimulating factor (hGM-CSF): identification of a binding site for a neutralizing antibody. Growth Factors. 1990; 3(2):159-169.
28. DiGiacomo RA, Xie L, Cullen C, Indelicato SR. Development and validation of a kinetic assay for analysis of anti-human interleukin-5 monoclonal antibody (SCH 55700) and human interleukin-5 interactions using surface plasmon resonance. Anal Biochem. 2004;327(2):165-175.
29. Conti L, Cardone M, Varano B, Puddu P, Belardelli F, Gessani S. Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol. 2008;38(3):750-762.
30. Takahashi GW, Andrews DF III, Lilly MB, Singer JW, Alderson MR. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood. 1993;81(2): 357-364.
31. Wang J, Liu Y, Li Z, et al. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood. 2010;116(26):5991-6002.
32. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol. 2011;152(6):677-687.
33. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012; 120(15):3080-3088.
34. Kalaitzidis D, Gilliland DG. Going with the flow: JAK-STAT signaling in JMML. Cancer Cell. 2008; 14(4):279-280.
35. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
36. Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351-1361.
37. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3): 840-849.
38. Aul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992; 6(1):52-59.